Johnson & Johnson Therapy Nipocalimab Granted U.S. FDA Fast Track Designation in Systemic Lupus Erythematosus
March 04, 2026
March 04, 2026
RARITAN, New Jersey, March 4 -- Johnson and Johnson Innovative Medicine issued the following news release on March 3, 2026:
* * *
Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)
Fast Track designation reflects the unmet need in this serious disease and enables the potential for an accelerated FDA review timeline
The designation is supported by a Phase 2 study in which nipoc . . .
* * *
Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)
Fast Track designation reflects the unmet need in this serious disease and enables the potential for an accelerated FDA review timeline
The designation is supported by a Phase 2 study in which nipoc . . .